Key facts
- It has raised $187.0M; the latest was Early Stage VC ($187.0M) in May 2025.
- Notable investors include Norwest, Novo Holdings, EDBI, SEEDS Capital, Frazier Healthcare Partners — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Callio Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Callio Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Callio Therapeutics
Developer of a multi-payload antibody-drug conjugate designed to maximize therapeutic benefit for cancer patients. The company engages in developing ADCs that have differentiated payload and linker technologies that allow targeted delivery of drug combinations to tumor cells, enabling healthcare professionals to treat cancers.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2024
- Employees
- 10
- Website
- calliotx.com/
- Ownership
- Privately Held (backing)
Callio Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Callio Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Callio Therapeutics in its N-PORT filings yet. We sweep new filings monthly.